Quick Answer
Bicara Therapeutics Inc. reported Diluted EPS of $2.52 per share (loss) for fiscal year 2025.
Bicara Therapeutics Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.52 | +37.8% |
| 2024 | -$4.05 | +95.5% |
| 2023 | -$89.61 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.67 | +58.1% | -34.0% |
| June 30, 2025 | -$0.50 | +97.4% | +26.5% |
| March 31, 2025 | -$0.68 | +96.4% | +57.5% |
| September 30, 2024 | -$1.60 | +95.8% | +91.6% |
| June 30, 2024 | -$19.01 | — | -0.4% |
| March 31, 2024 | -$18.94 | — | +50.5% |
| September 30, 2023 | -$38.23 | — | — |
- Bicara Therapeutics Inc. showed an increase of +37.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, Bicara Therapeutics Inc.’s diluted eps has grown by 97.2% (from $89.61 per share (loss) to $2.52 per share (loss)).
- The most recent figure is from Bicara Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: